No Data
No Data
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment
Bristol-Myers Squibb (BMY) said Thursday that additional data from the EMERGENT-5 trial supports KarXT's potential as a unique schizophrenia treatment. The long-term trials, consistent with short-term
Express News | Bristol Myers Squibb To Present KarXT Data At ASCP May 28-31
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
Bristol-Myers Squibb Options Spot-On: On May 22nd, 68,057 Contracts Were Traded, With 658.5K Open Interest
On May 22nd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 68,057 options for the day, of which put options accounted for 58.6% of the total transactions
Bristol-Myers Squibb Snaps Six Days of Losses, Trades in the Green
Bristol-Myers Squibb (NYSE:BMY) shares traded in the green on Tuesday, breaking six straight days of losses.
Express News | NYSE Order Imbalance 482454.0 Shares on Sell Side
No Data